Astria Therapeutics (ATXS)
(Delayed Data from NSDQ)
$9.47 USD
+0.46 (5.11%)
Updated May 31, 2024 04:00 PM ET
After-Market: $9.48 +0.01 (0.11%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth C Momentum F VGM
Brokerage Reports
Astria Therapeutics, Inc. [ATXS]
Reports for Purchase
Showing records 21 - 40 ( 69 total )
Company: Astria Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
New Strategic Leaf Turned Over With OX40 Transaction,Raise
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Astria Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Astria Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Pipeline Added To As Planned with Early-Stage STAR-0310; Price Target Adjusted Down to $18
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Astria Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Astria Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
STAR(-0215) Gazing -- Looking Ahead to Next Data Updates
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Astria Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
2Q23 Results; STAR-0215''s Potential Brightens
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Astria Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
1Q23 Results; STAR-0215 Momentum Continues to Build
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Astria Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
All Cylinders Firing as ALPHA-STAR Progresses [1Q23 Highlights]
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Astria Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Astria Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Model Behavior; Mechanistic Modeling Data Strengthen Long-Term Dosing Profile of STAR-0215
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Astria Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Notes From The (Virtual) Road... Shooting Their Shot With STAR-0215
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Astria Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Astria Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Astria Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Astria Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Astria Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Astria Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Astria Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
2022 Results; STAR-0215 Continues to Shine; Initial Phase 2b Data Expected Mid-2024
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Astria Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Astria Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Long Live STAR-0215; Further Data Supporting Long- Acting Profile; Additional Phase 1a Results Expected 4Q23
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J